iGlarLixi vs. Premixed Insulin Initiation in Adults with Type 2 Diabetes (T2D) Advancing from Basal Insulin (BI) Therapy: SoliComplex Real-World Study

被引：5
|
作者：
Lajara, Rosemarie
Heller, Caroline
Pantalone, Kevin M.
Lew, Elisheva
Li, Xuan
Dex, Terry A.
Kilpatrick, Rachel
机构：
来源：
DIABETES | 2022年 / 71卷
关键词：
D O I：
10.2337/db22-739-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
739-P
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Insulin intensification with basal plus mealtime insulin or mid-mixture premixed insulin in type 2 diabetes in real-world clinical practice
    Yang, Yi-Sun
    Huang, Chien-Ning
    Kornelius, Edy
    Lo, Shih-Chang
    Wu, Yueh-Chu
    Li, Ching-Lu
    Lin, Yu-Tze
    Hsiao, Hui-Wen
    Chia, Tin-Wen
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2016, 120 : S94 - S95
  • [22] Efficacy and safety of iGlarLixi vs insulin glargine 100 U/ml in Chinese people with type 2 diabetes (T2D) inadequately controlled on basal insulin (BI): LixiLan-L-China trial
    Guo, X.
    Zhang, J.
    Dong, X.
    Lu, Y.
    Pang, W.
    Gu, S.
    Ping, L.
    Nian, G.
    Niemoeller, E.
    Souhami, E.
    DIABETOLOGIA, 2021, 64 (SUPPL 1) : 270 - 270
  • [23] Intensified insulin therapy of type 2 diabetes mellitus: Insulin glargine vs. insulin detemir as basal insulin
    Jungmann, Eckart
    DIABETES, 2006, 55 : A118 - A118
  • [24] Dulaglutide (DU) Has Better Glycemic Effectiveness vs. Basal Insulin (BI) in Injection-Naive Patients with Type 2 Diabetes (T2D): The DISPELTM Study
    Mody, Reema
    Huang, Qing
    Yu, Maria
    Zhang, Xian
    Wang, Liya
    Grabner, Michael
    Patel, Hiren
    DIABETES, 2019, 68
  • [25] Digital-Tool-Supported Basal Insulin (BI) Titration: Real-World Effectiveness of My Dose Coach (MDC) in People with Type 2 Diabetes (T2D) in Colombia
    Gomez, Ana Maria
    Rincon, Alex Ramirez
    Feriz, Karen
    Salamanca, Carlos F.
    Silva, Liliana P.
    DIABETES, 2022, 71
  • [26] Glycemic Control and Adherence to Basal Insulin Therapy in Taiwanese Patients with Type 2 Diabetes (T2D)
    Chien, Ming-Nan
    Chen, Yen-Ling
    Hung, Yi-Jen
    Wang, Shu-Yi
    Lu, Wen-Tsung
    Chen, Chih-Hung
    Lin, Ching-Ling
    Huang, Tze-Pao
    Tsai, Ming-Han
    Tseng, Wei-Kung
    Wu, Ta-Jen
    Ho, Cheng
    Lin, Wen-Yu
    Chen, Bill
    Chuang, Lee-Ming
    DIABETES, 2014, 63 : A600 - A600
  • [27] Real-World Persistence, Adherence, Health Care Resource Utilization, and Costs in People with Type 2 Diabetes (T2D) Switching from Basal Insulin (BI) to Second-Generation BI (Insulin Glargine 300 U/mL [Gla-300]) vs. First-Generation BI (Insulin Glargine 1
    Wright, Eugene
    Gill, Jasvinder
    Huse, Samuel
    Li, Xuan
    Reid, Timothy
    Zhou, Fang L.
    DIABETES, 2021, 70
  • [28] EFFECTIVENESS OF MY DOSE COACH (MDC) USE DURING BASAL INSULIN (BI) TITRATION IN TYPE 2 DIABETES (T2D): REAL-WORLD DATA FROM ALGERIA, COLOMBIA, INDIA AND MEXICO
    Viswanathan, V.
    Unnikrishnan, A. G.
    Lubwama, R.
    Zhou, F. L.
    Bertolini, M.
    Botero, J.
    Mancillas-Adame, L.
    Baghous, H.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2022, 24 : A30 - A31
  • [29] Predictors and Clinical Outcomes of Treatment Intensification in Patients (Pts) with T2D Uncontrolled on Basal Insulin (BI) in Real-World Settings
    Kallenbach, Lee
    Ye, Fen
    Fan, Tao
    Hu, Wenli
    Levin, Phillip A.
    DIABETES, 2017, 66 : A45 - A45
  • [30] Switching from Premixed Insulin to Insulin Degludec/Insulin Aspart for the Management of Type 2 Diabetes Mellitus: Implications of a Real-World Study on Insulin Degludec Dosing
    Yiming Wu
    Junqing Zhang
    Ang Li
    Diabetes Therapy, 2024, 15 (12) : 2515 - 2523
12345